Nasdaq: SUPN Archives · BioBuzz

Loading …

Rockville’s Supernus Announces FDA Approval of Qelbree™ (SPN-812) for the Treatment of ADHD

<img width="300" height="300" alt="" data-srcset="https://biobuzz.io/wp-content/uploads/2021/04/supernus-pharmaceuticals-300x300.jpg 300w, https://biobuzz.io/wp-content/uploads/2021/04/supernus-pharmaceuticals-150x150.jpg 150w, https://biobuzz.io/wp-content/uploads/2021/04/supernus-pharmaceuticals-75x75.jpg 75w" data-src="https://biobuzz.io/wp-content/uploads/2021/04/supernus-pharmaceuticals-300x300.jpg" data-sizes="(max-width: 300px) 100vw, 300px" class="attachment-biobuzz-medium size-biobuzz-medium wp-post-image lazyload lazyload" src="data:image/gif;base64,R0lGODlhAQABAAAAACH5BAEKAAEALAAAAAABAAEAAAICTAEAOw==" /><noscript><img width="300" height="300" src="https://biobuzz.io/wp-content/uploads/2021/04/supernus-pharmaceuticals-300x300.jpg" class="attachment-biobuzz-medium size-biobuzz-medium wp-post-image lazyload" alt="" srcset="https://biobuzz.io/wp-content/uploads/2021/04/supernus-pharmaceuticals-300x300.jpg 300w, https://biobuzz.io/wp-content/uploads/2021/04/supernus-pharmaceuticals-150x150.jpg 150w, https://biobuzz.io/wp-content/uploads/2021/04/supernus-pharmaceuticals-75x75.jpg 75w" sizes="(max-width: 300px) 100vw, 300px" />

Published on : April 2, 2021April 3, 2021 Published by : BioBuzz Media

Supernus Announces FDA Approval of Qelbree™ (SPN-812) for the Treatment of ADHD ROCKVILLE, Md., April 02, 2021 (GLOBE NEWSWIRE) — Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products [….]